RCS - Futura Medical PLC - Clinical trial data presented at SMSNA

Futura MedicalAnnouncement

17/10/2024 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241017:nRSQ4942Ia&default-theme=true

RNS Number : 4942I  Futura Medical PLC  17 October 2024

17 October
2024

Futura Medical plc

("Futura", "the Group" or the "Company")

Clinical trial data presented at SMSNA

 

Futura Medical plc (AIM: FUM), the consumer healthcare company behind
Eroxon(®), that specialises in the development and global commercialisation
of innovative and clinically proven sexual health products, announces that
three abstracts on MED3000 are being presented at the Sexual Medicine Society
of North America (SMSNA) at their annual conference in Scottsdale, Arizona on
17(th) to 20(th) October. The SMSNA promotes, encourages, and supports the
highest standards of practice, research, education, and ethics in the study of
human sexual function and dysfunction.

 

The abstracts detail the results of clinical trials, showing the positive
impact of MED3000 on Erectile Dysfunction (ED) but also self-esteem and
relationships in men with ED and sexual encounter profiles for men and their
partners.

 

The importance of the presentation of these abstracts is to educate and
improve awareness amongst key opinion leaders and other healthcare
practitioners about the benefits of MED3000 (now available through the USA
under the brand name Eroxon(®)) as a clinical proven treatment for ED.

 

Details of the of the abstracts, methods and results can be found at:
https://www.smsna.org/annual2024/program
(https://www.smsna.org/annual2024/program)

 

 Abstract 1  Topical Administration of MED3000 Gel Significantly Improves Self-esteem and
             Relationships in Men with Erectile Dysfunction: Results from Two Clinical
             Trials
 Abstract 2  Topical Administration of MED3000 Gel Significantly Improves Erectile Function
             in Men with Mild, Moderate, or Severe Erectile Dysfunction: Results from Two
             Multicenter Clinical Trials
 Abstract 3  Topical Administration of MED3000 Gel Significantly Improves All Aspects of
             the Sexual Encounter Profile for Both Men and Their Partners

 

The abstracts are presented to the audience and then all abstracts presented
at the meeting will be published in a supplement of the Journal of Sexual
Medicine.

 

 

Contacts:

 Futura Medical plc              James Barder                         investor.relations@futuramedical.com

                                    (mailto:Investor.relations@futuramedical.com)
                                 Chief Executive Officer

                                    +44 (0)1483 685 670
                                 Angela Hildreth

                                    www.futuramedical.com (http://www.futuramedical.com/)
                                 Finance Director and COO

 Panmure Liberum                 Emma Earl, Will Goode,               +44 (0)20 3100 2000

Mark Rogers (Corporate Finance)

 Nominated Adviser

                               Rupert Dearden (Corporate Broking)

 and Broker

 Stifel Nicolaus Europe Limited  Alan Selby                           +44 (0)207 710 7600

 Joint Broker                    Ben Maddison

 Alma Strategic Communications   Rebecca Sanders-Hewett               +44 (0)20 3405 0205

                                 Sam Modlin                           futura@almastrategic.com

                                 Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLBDGLBBDGSL